RxDoctor Payments Data

Kyle Anderson

Family · Riverton, WYNPI 1316309610

Payments from drug & device makers

$378in general payments, 2019–2025

Across 20 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$123
  • AstraZeneca$73
  • Lilly USA, LLC$60
  • GSK$55
  • Organon$20
  • Novo Nordisk$18
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie7$123
AstraZeneca4$73
Lilly USA, LLC1$60
GSK3$55
Organon2$20
Novo Nordisk1$18
Boston Scientific1$15
Medtronic1$14

How this compares

$378 in reported general payments places this provider in the 60th percentile of 284 family providers in Wyoming.

See all family providers in Wyoming

Medicare billing

Part B allowed, 2024
$2,217
Medicare patients
79
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$100,013
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$68,008
JardianceEmpagliflozin86$64,854
EliquisApixaban32$25,949
MounjaroTirzepatide24$22,751
TrulicityDulaglutide15$18,547
FarxigaDapagliflozin Propanediol26$16,850
Breo ElliptaFluticasone/Vilanterol31$15,322
Combivent RespimatIpratropium/Albuterol Sulfate15$12,381
Tresiba Flextouch U-200Insulin Degludec13$11,721
Repatha SureclickEvolocumab12$6,766
Ventolin HfaAlbuterol Sulfate68$4,409
Albuterol Sulfate HfaAlbuterol Sulfate106$3,788
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$3,154
Gabapentin184$2,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$100,01388 claims
GSKTrelegy Ellipta, Breo Ellipta$55$83,32998 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin N$60$41,98854 claims
AstraZenecaFarxiga$73$16,85026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 284 family providers in Wyoming.

Other family in Riverton

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →